Document is current

Documents that mention this clinical trial

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
https://doi.org/10.1136/rmdopen-2022-002612

Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
https://doi.org/10.1136/jitc-2019-000234

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
https://doi.org/10.1136/jitc-2020-000878

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
https://doi.org/10.1136/jitc-2020-001996

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007310

Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.9538

Circulating tumour cell clusters: isolation, biological significance and therapeutic implications
https://doi.org/10.1136/bmjonc-2024-000437

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814

Predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: A Simon phase II trial (NCT03999749).
https://doi.org/10.1200/jco.2024.42.23_suppl.222

816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
https://doi.org/10.1136/jitc-2021-sitc2021.816

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
https://doi.org/10.1136/jitc-2020-000842

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
https://doi.org/10.1136/jitc-2020-001145

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111

Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.
https://doi.org/10.1200/jco.2024.42.16_suppl.9553

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
https://doi.org/10.1136/jitc-2021-003551

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814

816 Selective immune suppression using interleukin-6 blockade in immune related adverse events
https://doi.org/10.1136/jitc-2021-sitc2021.816

Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776

Documents that mention this clinical trial

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications
https://doi.org/10.1136/jitc-2024-011427

Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer
https://doi.org/10.1136/jitc-2024-010612

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007310

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
https://doi.org/10.1136/jitc-2022-005111